Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Employees

316

Sector

Biotechnology & Medical Research

Calendar

03-11 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
12/12/25	3.790 $	-7.11%	836,731
11/12/25	4.080 $	-0.24%	246,490
10/12/25	4.090 $	+4.34%	494,094
09/12/25	3.920 $	-2.73%	478,956
08/12/25	4.030 $	+2.54%	490,739

Delayed Quote Nasdaq, December 12, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.790USD

Average target price

12.33USD

Spread / Average Target

+225.42%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 12/12/2025 GMT			5-day change	1st Jan Change
3.790 ^USD	-7.11%		-3.56%	+38.32%

12-04	Agenus Inc. - Shareholder/Analyst Call
11-18	Agenus Inc. Appoints Dr. José Iglesias as Chief Medical Affairs Officer, Effective November 10, 2025	CI

Capitalization	129M 110M 103M 96.5M 178M 11.67B 194M 1.2B 464M 5.5B 484M 473M 20.08B	P/E ratio 2025 *	4x	P/E ratio 2026 *	-11x
Enterprise value	129M 110M 103M 96.5M 178M 11.67B 194M 1.2B 464M 5.5B 484M 473M 20.08B	EV / Sales 2025 *	0.89x	EV / Sales 2026 *	1.05x
Free-Float	98.75%	Yield 2025 *	-	Yield 2026 *	-

12-04	Agenus Inc. - Shareholder/Analyst Call
11-18	Agenus Inc. Appoints Dr. José Iglesias as Chief Medical Affairs Officer, Effective November 10, 2025	CI
11-18	Agenus appoints Dr. José Iglesias as chief medical affairs officer to guide global medical affairs and early-access programs, including France's AAC	RE
11-10	Agenus Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
10-22	Agenus Inc. - Shareholder/Analyst Call
10-17	Agenus Reports 39% of Patients Alive At Two- Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025	CI
10-07	Agenus Inc. announced that it expects to receive $10 million in funding	CI
09-23	Agenus - Closing of deals with Zydus Pharmaceuticals - SEC filing	RE
09-09	France authorizes reimbursed compassionate use of Agenus' BOT/BAL for MSS metastatic colorectal cancer	RE
09-09	Agenus Inc. Announces Its Investigational Combination Botensilimab Plus Balstilimab (BOT/BAL) Is Now Available to Eligible Patients with Refractory Microsatellite-Stable Metastatic Colorectal Cancer Under France?s Compassionate Access (Accès Compassionnel, or AAC) Framework	CI
09-01	Agenus Inc., Q2 2025 Earnings Call, Aug 27, 2025
08-11	Agenus Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
07-31	Agenus to provide corporate update and second quarter 2025 financial report	RE

06-04	HC Wainwright Upgrades Agenus to Buy From Neutral, $25 Price Target	MT
04-21	B. Riley Cuts Price Target on Agenus to $8 From $11, Keeps Buy Rating	MT
11-18	B. Riley Adjusts Agenus Price Target to $11 From $18, Maintains Buy Rating	MT
14/08/24	B. Riley Adjusts Price Target on Agenus to $18 From $42, Maintains Buy Rating	MT
19/07/24	HC Wainwright Downgrades Agenus to Neutral From Buy, Adjusts Price Target to $9 From $40	MT

Agenus Inc. Share Price

Equities

AGEN

US00847G8042

Biotechnology & Medical Research

Valuation: Agenus Inc.

Chart: Agenus Inc.

Latest news: Agenus Inc.

Last Transcript: Agenus Inc.

Analysts' recommendations: Agenus Inc.

Press Releases: Agenus Inc.

News in other languages: Agenus Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Agenus Inc.

ETFs: Agenus Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

11-19	Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL	BU
11-18	Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC	BU
11-10	Agenus: Q3 Earnings Snapshot	AQ
11-10	Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances	BU
11-05	Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report	BU

09-09	Francia otorga acceso compasivo (AAC) reembolsado para el tratamiento BOT/BAL de Agenus en el cáncer colorrectal metastásico refractario con MSS
09-09	La France accorde une autorisation d'accès compassionnel remboursable au BOT/BAL d’Agenus dans le cancer colorectal métastatique MSS réfractaire
09-09	Frankreich gewährt erstattungsfähigen Compassionate-Use-Zugang (AAC) zu BOT/BAL von Agenus bei refraktärem MSS-metastasiertem kolorektalem Karzinom
06-04	Agenus et Zydus Lifesciences concluent une collaboration stratégique de 141 millions de dollars pour développer BOT/BAL et étendre les capacités de production de produits biologiques de Zydus aux États-Unis
06-04	Agenus y Zydus Lifesciences acuerdan una colaboración estratégica valuada en USD 141 millones para impulsar las inmunoterapias BOT/BAL, y expandir la fabricación de productos biológicos de Zydus en EE. UU.

1 day	-7.11%
1 week	-3.56%
Current month	-16.89%
1 month	-12.47%
3 months	-15.40%
6 months	-19.36%
Current year	+38.32%

1 week	3.78	4.12
1 month	3.78	4.64
Current year	1.38	7.34
1 year	1.38	7.34
3 years	1.38	61.39
5 years	1.38	135.8
10 years	1.38	149.8

Manager	Title	Age	Since
Garo Armen CEO	Chief Executive Officer	72	30/03/1994
Jennifer Buell PSD	President	51	06/11/2018
Christine Klaskin DFI	Director of Finance/CFO	59	30/09/2006

Director	Title	Age	Since
Garo Armen CHM	Chairman	72	03/11/2010
Brian Corvese BRD	Director/Board Member	67	07/03/2007
Timothy Wright BRD	Director/Board Member	67	06/12/2006

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
AGENUS INC.	-7.11%	-3.56%	+24.26%	-93.21%	129M
LONZA GROUP AG	-1.79%	-5.23%	-3.38%	+8.38%	45.43B
IQVIA HOLDINGS INC.	-1.65%	-1.59%	+11.65%	+2.52%	37.85B
BEONE MEDICINES AG	-0.55%	-1.19%	+77.90%	+53.34%	35.31B
CELLTRION, INC.	+0.05%	+1.91%	+5.47%	+18.52%	27.66B
MEDPACE HOLDINGS, INC.	-1.46%	+1.78%	+61.28%	+159.86%	15.72B
REVOLUTION MEDICINES, INC.	+0.52%	-0.90%	+75.34%	+238.71%	15.26B
ICON PUBLIC LIMITED COMPANY	-1.76%	+0.38%	-10.36%	-5.89%	14.25B
ASCENDIS PHARMA A/S	+4.88%	+7.29%	+69.72%	+79.48%	13.47B
IONIS PHARMACEUTICALS, INC.	+2.12%	-1.05%	+120.76%	+111.96%	13.09B
Average	-0.68%	-0.42%	+43.26%	+57.37%	21.82B
Weighted average by Cap.	-0.50%	-1.10%	+35.19%	+52.56%

	2025 *	2026 *
Net sales	146M 124M 116M 109M 201M 13.19B 219M 1.35B 525M 6.22B 546M 535M 22.69B	123M 105M 97.77M 91.99M 169M 11.13B 185M 1.14B 443M 5.25B 461M 451M 19.14B
Net income	63.5M 54.1M 50.53M 47.54M 87.53M 5.75B 95.62M 590M 229M 2.71B 238M 233M 9.89B	-77.55M -66.06M -61.71M -58.06M -107M -7.02B -117M -720M -279M -3.31B -291M -285M -12.08B
Net Debt	-	-